1. Home
  2. STTK vs UG Comparison

STTK vs UG Comparison

Compare STTK & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • UG
  • Stock Information
  • Founded
  • STTK 2016
  • UG 1942
  • Country
  • STTK United States
  • UG United States
  • Employees
  • STTK N/A
  • UG N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • UG Package Goods/Cosmetics
  • Sector
  • STTK Health Care
  • UG Consumer Discretionary
  • Exchange
  • STTK Nasdaq
  • UG Nasdaq
  • Market Cap
  • STTK 37.6M
  • UG 36.9M
  • IPO Year
  • STTK 2020
  • UG N/A
  • Fundamental
  • Price
  • STTK $1.00
  • UG $8.30
  • Analyst Decision
  • STTK Hold
  • UG
  • Analyst Count
  • STTK 4
  • UG 0
  • Target Price
  • STTK $3.00
  • UG N/A
  • AVG Volume (30 Days)
  • STTK 112.0K
  • UG 3.4K
  • Earning Date
  • STTK 07-31-2025
  • UG 08-08-2025
  • Dividend Yield
  • STTK N/A
  • UG 8.53%
  • EPS Growth
  • STTK N/A
  • UG 4.93
  • EPS
  • STTK N/A
  • UG 0.63
  • Revenue
  • STTK $4,606,000.00
  • UG $11,408,154.00
  • Revenue This Year
  • STTK N/A
  • UG N/A
  • Revenue Next Year
  • STTK N/A
  • UG N/A
  • P/E Ratio
  • STTK N/A
  • UG $13.29
  • Revenue Growth
  • STTK 69.65
  • UG N/A
  • 52 Week Low
  • STTK $0.69
  • UG $7.73
  • 52 Week High
  • STTK $4.99
  • UG $16.25
  • Technical
  • Relative Strength Index (RSI)
  • STTK 47.54
  • UG 51.30
  • Support Level
  • STTK $0.91
  • UG $8.10
  • Resistance Level
  • STTK $1.14
  • UG $8.35
  • Average True Range (ATR)
  • STTK 0.08
  • UG 0.18
  • MACD
  • STTK -0.01
  • UG 0.01
  • Stochastic Oscillator
  • STTK 28.35
  • UG 56.52

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About UG United-Guardian Inc.

United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.

Share on Social Networks: